Align Technology, Inc.: peers
Align Technology, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Bio-Rad Laboratories, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Align Technology, Inc.base ALGN · 🇺🇸 US Percentile in Healthcare Percentile in USA | Globus Medical, Inc. GMED · 🇺🇸 US Percentile in Healthcare Percentile in USA | Insulet Corporation PODD · 🇺🇸 US Percentile in Healthcare Percentile in USA | Bio-Rad Laboratories, Inc. BIO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Bruker Corporation BRKR · 🇺🇸 US Percentile in Healthcare Percentile in USA | Penumbra, Inc. PEN · 🇺🇸 US Percentile in Healthcare Percentile in USA | Zimmer Biomet Holdings, Inc. ZBH · 🇺🇸 US Percentile in Healthcare Percentile in USA | Integer Holdings Corporation ITGR · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $10.7 BOct 22, 2026 · Market data4th of 8 | $10.9 BOct 26, 2026 · Market data3rd of 8 | $10.4 BOct 27, 2026 · Market data5th of 8 | $9.5 BAug 1, 2026 · Market data6th of 8 | $9.1 BOct 27, 2026 · Market data7th of 8 | $12.8 BOct 27, 2026 · Market data2nd of 8 | $18.2 BOct 29, 2026 · Market data1st of 8 | $4.3 BOct 27, 2026 · Market data8th of 8 | $10.5 B8 ranked |
| Revenue (Better neither way: ranked highest first) | $4.0 BFY2025 · SEC2nd of 8 | $2.9 BFY2025 · SEC4th of 8 | $2.7 BFY2025 · SEC5th of 8 | $2.6 BFY2025 · SEC6th of 8 | $3.4 BFY2025 · SEC3rd of 8 | $1.4 BFY2025 · SEC8th of 8 | $8.2 BFY2025 · SEC1st of 8 | $1.9 BFY2025 · SEC7th of 8 | $2.8 B8 ranked |
| Net income (Higher is better) | $410 MFY2025 · SEC4th of 8 | $538 MFY2025 · SEC3rd of 8 | $247 MFY2025 · SEC5th of 8 | $760 MFY2025 · SEC1st of 8 | $-9 MFY2025 · SEC8th of 8 | $178 MFY2025 · SEC6th of 8 | $705 MFY2025 · SEC2nd of 8 | $103 MFY2025 · SEC7th of 8 | $329 M8 ranked |
| Employees (Better neither way: ranked highest first) | 20,290December 31, 2025 · Profile1st of 8 | 6,000December 31, 2025 · Profile6th of 8 | 5,400December 31, 2025 · Profile7th of 8 | 7,450December 31, 2025 · Profile5th of 8 | 11,085December 31, 2025 · Profile3rd of 8 | 4,700December 31, 2025 · Profile8th of 8 | 17,000December 31, 2025 · Profile2nd of 8 | 9,000As on 2021 · Profile4th of 8 | 8,2258 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | +0.9%FY2025 · SEC7th of 828th31st | +16.6%FY2025 · SEC3rd of 862nd74th | +30.7%FY2025 · SEC1st of 877th87th | +0.7%FY2025 · SEC8th of 827th31st | +2.1%FY2025 · SEC6th of 831st35th | +17.5%FY2025 · SEC2nd of 864th75th | +7.2%FY2025 · SEC5th of 843rd53rd | +8.0%FY2025 · SEC4th of 844th55th | +7.6%8 ranked |
| Revenue growth, 3 years a year (Higher is better) | +2.6%FY2025 · SEC7th of 835th43rd | +42.2%FY2025 · SEC1st of 887th95th | +27.5%FY2025 · SEC2nd of 879th90th | -2.7%FY2025 · SEC8th of 820th24th | +10.7%FY2025 · SEC5th of 855th71st | +18.3%FY2025 · SEC3rd of 870th83rd | +5.8%FY2025 · SEC6th of 844th56th | +11.7%FY2025 · SEC4th of 857th73rd | +11.2%8 ranked |
| Earnings per share growth (Higher is better) | +0.5%FY2025 · SEC2nd of 538th38th | +422.7%FY2025 · SEC1st of 597th98th | -39.8%FY2025 · SEC5th of 512th13th | ———— | ———— | ———— | -19.9%FY2025 · SEC4th of 522nd21st | -14.0%FY2025 · SEC3rd of 524th25th | -14.0%5 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | 67.2%FY2025 · SEC4th of 863rd80th | 67.4%FY2025 · SEC3rd of 864th80th | 71.6%FY2025 · SEC1st of 871st84th | 51.9%FY2025 · SEC6th of 839th66th | 45.9%FY2025 · SEC7th of 831st59th | 67.1%FY2025 · SEC5th of 863rd80th | 69.7%FY2025 · SEC2nd of 868th82nd | 27.0%FY2025 · SEC8th of 813th30th | 67.2%8 ranked |
| Operating margin (Higher is better) | 13.5%FY2025 · SEC3rd of 880th76th | 16.3%FY2025 · SEC2nd of 883rd80th | 17.5%FY2025 · SEC1st of 885th82nd | 1.8%FY2025 · SEC8th of 861st45th | 2.0%FY2025 · SEC7th of 861st45th | 13.5%FY2025 · SEC4th of 880th75th | 13.3%FY2025 · SEC5th of 879th75th | 11.9%FY2025 · SEC6th of 876th73rd | 13.4%8 ranked |
| Net margin (Higher is better) | 10.2%FY2025 · SEC4th of 880th75th | 18.3%FY2025 · SEC2nd of 889th87th | 9.1%FY2025 · SEC5th of 878th73rd | 29.4%FY2025 · SEC1st of 894th94th | -0.3%FY2025 · SEC8th of 860th42nd | 12.7%FY2025 · SEC3rd of 882nd80th | 8.6%FY2025 · SEC6th of 877th71st | 5.5%FY2025 · SEC7th of 871st63rd | 9.6%8 ranked |
| Free cash flow margin (Higher is better) | 12.2%FY2025 · SEC6th of 875th75th | 20.0%FY2025 · SEC1st of 888th88th | 13.9%FY2025 · SEC4th of 879th79th | 14.5%FY2025 · SEC3rd of 880th80th | 1.3%FY2025 · SEC8th of 855th39th | 12.5%FY2025 · SEC5th of 876th75th | 17.9%FY2025 · SEC2nd of 885th85th | 5.7%FY2025 · SEC7th of 864th56th | 13.2%8 ranked |
| Return on equity (Higher is better) | 10.4%FY2025 · SEC5th of 881st66th | 12.3%FY2025 · SEC3rd of 884th72nd | 18.1%FY2025 · SEC1st of 889th83rd | 10.8%FY2025 · SEC4th of 882nd68th | -0.4%FY2025 · SEC8th of 872nd41st | 13.8%FY2025 · SEC2nd of 886th75th | 5.6%FY2025 · SEC7th of 877th52nd | 6.1%FY2025 · SEC6th of 877th53rd | 10.6%8 ranked |
| Return on invested capital (Higher is better) | ———— | ———— | ———— | 0.5%FY2025 · SEC3rd of 34th2nd | ———— | ———— | 5.1%FY2025 · SEC2nd of 318th17th | 6.6%FY2025 · SEC1st of 326th27th | 5.1%3 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | 21.7×price Oct 22, 2026 · Market data5th of 634th57th | 19.6×price Oct 26, 2026 · Market data6th of 631st51st | 24.1×price Oct 27, 2026 · Market data3rd of 641st62nd | 9.3׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 81.6×price Oct 27, 2026 · Market data1st of 685th93rd | 23.8×price Oct 29, 2026 · Market data4th of 641st61st | 41.5×price Oct 27, 2026 · Market data2nd of 665th83rd | 24.0×6 ranked |
| Price to sales (Better neither way: ranked highest first) | 2.6×price Oct 22, 2026 · Market data5th of 739th55th | 3.5×price Oct 26, 2026 · Market data2nd of 749th66th | 3.3×price Oct 27, 2026 · Market data3rd of 746th63rd | 3.7׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 2.6×price Oct 27, 2026 · Market data4th of 740th55th | 8.2×price Oct 27, 2026 · Market data1st of 770th87th | 2.1×price Oct 29, 2026 · Market data7th of 734th50th | 2.4×price Oct 27, 2026 · Market data6th of 737th53rd | 2.6×7 ranked |
| Price to book (Better neither way: ranked highest first) | 2.6×price Oct 22, 2026 · Market data4th of 744th57th | 2.4×price Oct 26, 2026 · Market data6th of 742nd54th | 6.8×price Oct 27, 2026 · Market data2nd of 776th83rd | 1.3׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 3.7×price Oct 27, 2026 · Market data3rd of 757th69th | 9.0×price Oct 27, 2026 · Market data1st of 782nd88th | 1.4×price Oct 29, 2026 · Market data7th of 728th35th | 2.5×price Oct 27, 2026 · Market data5th of 743rd55th | 2.6×7 ranked |
| Free cash flow yield (Higher is better) | 4.6%price Oct 22, 2026 · Market data3rd of 785th64th | 5.4%price Oct 26, 2026 · Market data2nd of 788th68th | 3.6%price Oct 27, 2026 · Market data4th of 781st58th | 3.9%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 0.5%price Oct 27, 2026 · Market data7th of 770th39th | 1.4%price Oct 27, 2026 · Market data6th of 773rd43rd | 8.1%price Oct 29, 2026 · Market data1st of 793rd81st | 2.4%price Oct 27, 2026 · Market data5th of 777th49th | 3.6%7 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | 0.2×FY2025 · SEC1st of 429th20th | 0.8×FY2025 · SEC4th of 468th59th | ———— | 0.6×FY2025 · SEC2nd of 456th47th | 0.7×FY2025 · SEC3rd of 463rd54th | 0.6×4 ranked |
| Net debt to EBITDA (Lower is better) | ———— | ———— | ———— | 3.2×FY2025 · SEC2nd of 469th65th | 5.4×FY2025 · SEC4th of 485th84th | ———— | 2.9×FY2025 · SEC1st of 468th61st | 3.3×FY2025 · SEC3rd of 472nd66th | 3.2×4 ranked |
| Interest cover (Higher is better) | ———— | ———— | ———— | 1.0×FY2025 · SEConly one with it75th53rd | ———— | ———— | ———— | ———— | 1.0×— |
| Piotroski F-score (Higher is better) | —— | —— | 6 of 9FY2025 · SEC1st of 5 | 5 of 9FY2025 · SEC2nd of 5 | 4 of 9FY2025 · SEC5th of 5 | —— | 5 of 9FY2025 · SEC2nd of 5 | 5 of 9FY2025 · SEC2nd of 5 | 5.0 of 95 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 13 of 23FY2025 · Scorecard6th of 8 | 18 of 23FY2025 · Scorecard1st of 8 | 16 of 23FY2025 · Scorecard3rd of 8 | 10 of 20FY2025 · Scorecard7th of 8 | 11 of 26FY2025 · Scorecard8th of 8 | 13 of 22FY2025 · Scorecard5th of 8 | 22 of 29FY2025 · Scorecard2nd of 8 | 16 of 26FY2025 · Scorecard4th of 8 | 60% passed8 ranked |
| Valuation checks (Higher is better) | 1 of 6FY2025 · Scorecard3rd of 7 | 4 of 6FY2025 · Scorecard1st of 7 | 1 of 6FY2025 · Scorecard3rd of 7 | —— | 0 of 6FY2025 · Scorecard6th of 7 | 0 of 6FY2025 · Scorecard6th of 7 | 4 of 6FY2025 · Scorecard1st of 7 | 1 of 6FY2025 · Scorecard3rd of 7 | 17% passed7 ranked |
| Growth checks (Higher is better) | 3 of 6FY2025 · Scorecard6th of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 5 of 6FY2025 · Scorecard3rd of 8 | 2 of 6FY2025 · Scorecard8th of 8 | 3 of 6FY2025 · Scorecard6th of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 4 of 6FY2025 · Scorecard5th of 8 | 5 of 6FY2025 · Scorecard3rd of 8 | 75% passed8 ranked |
| Profitability checks (Higher is better) | 3 of 5FY2025 · Scorecard4th of 8 | 3 of 5FY2025 · Scorecard4th of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 2 of 6FY2025 · Scorecard7th of 8 | 1 of 5FY2025 · Scorecard8th of 8 | 3 of 5FY2025 · Scorecard4th of 8 | 4 of 6FY2025 · Scorecard2nd of 8 | 4 of 6FY2025 · Scorecard2nd of 8 | 60% passed8 ranked |
| Financial health checks (Higher is better) | 3 of 3FY2025 · Scorecard1st of 8 | 3 of 3FY2025 · Scorecard1st of 8 | 3 of 3FY2025 · Scorecard1st of 8 | 4 of 6FY2025 · Scorecard8th of 8 | 4 of 5FY2025 · Scorecard6th of 8 | 3 of 3FY2025 · Scorecard1st of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 4 of 5FY2025 · Scorecard6th of 8 | 100% passed8 ranked |
| Shareholder returns checks (Higher is better) | 3 of 3FY2025 · Scorecard1st of 8 | 2 of 3FY2025 · Scorecard5th of 8 | 2 of 3FY2025 · Scorecard5th of 8 | 2 of 2FY2025 · Scorecard1st of 8 | 3 of 4FY2025 · Scorecard4th of 8 | 1 of 2FY2025 · Scorecard8th of 8 | 5 of 6FY2025 · Scorecard3rd of 8 | 2 of 3FY2025 · Scorecard5th of 8 | 71% passed8 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 101.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 89.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 106.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 66.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 87.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 88.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 98.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 115.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 93.6%8 ranked |
| Institutions holding (Better neither way: ranked highest first) | 6192026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 6152026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 6932026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 4172026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 4362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 4322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 9342026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 3522026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 5268 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | +6.1 pp2026-Q2 against 2026-Q1 · 13F2nd of 6 | +8.3 pp2026-Q2 against 2026-Q1 · 13F1st of 6 | +3.0 pp2026-Q2 against 2026-Q1 · 13F5th of 6 | —— | —— | +0.6 pp2026-Q2 against 2026-Q1 · 13F6th of 6 | +4.9 pp2026-Q2 against 2026-Q1 · 13F4th of 6 | +5.0 pp2026-Q2 against 2026-Q1 · 13F3rd of 6 | +4.9 pp6 ranked |
| Dividends | |||||||||
| Dividend yield (Higher is better) | ———— | ———— | ———— | ———— | 0.3%FY2025 · SEC2nd of 223rd9th | ———— | 1.0%FY2025 · SEC1st of 253rd28th | ———— | 0.6%2 ranked |
| Shareholder yield (Higher is better) | 4.4%FY2025 · SEC1st of 773rd63rd | 2.8%FY2025 · SEC3rd of 757th45th | 0.6%FY2025 · SEC5th of 726th16th | 3.1%†FY2025 · SECnot ranked: old priceold priceold price | 0.4%FY2025 · SEC6th of 723rd13th | 0.0%FY2025 · SEC7th of 77th3rd | 3.7%FY2025 · SEC2nd of 767th56th | 1.2%FY2025 · SEC4th of 736th24th | 1.2%7 ranked |
| Dividend payout (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | ———— | ———— | 27.0%FY2025 · SEConly one with it46th34th | ———— | 27.0%— |
| Dividend per share (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | —— | $0.96FY2025 · SEConly one with it | —— | $0.96— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Align Technology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Globus Medical, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Insulet Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Bio-Rad Laboratories, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Bruker Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Penumbra, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Zimmer Biomet Holdings, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Integer Holdings Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Align Technology, Inc. | 13.5%FY2025 | 80th percentile in Healthcaremedian -7.7%, 674 companies | 76th percentile in USAmedian 3.5%, 2,594 companies |
| Globus Medical, Inc. | 16.3%FY2025 | 83rd percentile in Healthcaremedian -7.7%, 674 companies | 80th percentile in USAmedian 3.5%, 2,594 companies |
| Insulet Corporation | 17.5%FY2025 | 85th percentile in Healthcaremedian -7.7%, 674 companies | 82nd percentile in USAmedian 3.5%, 2,594 companies |
| Bio-Rad Laboratories, Inc. | 1.8%FY2025 | 61st percentile in Healthcaremedian -7.7%, 674 companies | 45th percentile in USAmedian 3.5%, 2,594 companies |
| Bruker Corporation | 2.0%FY2025 | 61st percentile in Healthcaremedian -7.7%, 674 companies | 45th percentile in USAmedian 3.5%, 2,594 companies |
| Penumbra, Inc. | 13.5%FY2025 | 80th percentile in Healthcaremedian -7.7%, 674 companies | 75th percentile in USAmedian 3.5%, 2,594 companies |
| Zimmer Biomet Holdings, Inc. | 13.3%FY2025 | 79th percentile in Healthcaremedian -7.7%, 674 companies | 75th percentile in USAmedian 3.5%, 2,594 companies |
| Integer Holdings Corporation | 11.9%FY2025 | 76th percentile in Healthcaremedian -7.7%, 674 companies | 73rd percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Align Technology, Inc. | Globus Medical, Inc. | Insulet Corporation | Bio-Rad Laboratories, Inc. | Bruker Corporation | Penumbra, Inc. | Zimmer Biomet Holdings, Inc. | Integer Holdings Corporation |
|---|---|---|---|---|---|---|---|---|
| 2025 | $4.0 BSEC2nd | $2.9 BSEC4th | $2.7 BSEC5th | $2.6 BSEC6th | $3.4 BSEC3rd | $1.4 BSEC8th | $8.2 BSEC1st | $1.9 BSEC7th |
| 2024 | $4.0 BSEC2nd | $2.5 BSEC5th | $2.1 BSEC6th | $2.6 BSEC4th | $3.4 BSEC3rd | $1.2 BSEC8th | $7.7 BSEC1st | $1.7 BSEC7th |
| 2023 | $3.9 BSEC2nd | $1.6 BSEC6th | $1.7 BSEC5th | $2.7 BSEC4th | $3.0 BSEC3rd | $1.1 BSEC8th | $7.4 BSEC1st | $1.6 BSEC7th |
| 2022 | $3.7 BSEC2nd | $1.0 BSEC7th | $1.3 BSEC6th | $2.8 BSEC3rd | $2.5 BSEC4th | $847 MSEC8th | $6.9 BSEC1st | $1.3 BSEC5th |
| 2021 | $4.0 BSEC2nd | $958 MSEC7th | $1.1 BSEC6th | $2.9 BSEC3rd | $2.4 BSEC4th | $748 MSEC8th | $6.8 BSEC1st | $1.2 BSEC5th |
| 2020 | $2.5 BSEC3rd | $789 MSEC7th | $904 MSEC6th | $2.5 BSEC2nd | $2.0 BSEC4th | $560 MSEC8th | $6.1 BSEC1st | $1.1 BSEC5th |
| 2019 | $2.4 BSEC2nd | $785 MSEC6th | $738 MSEC7th | $2.3 BSEC3rd | $2.1 BSEC4th | $547 MSEC8th | $7.0 BSEC1st | $1.3 BSEC5th |
| 2018 | $2.0 BSEC3rd | $713 MSEC6th | $564 MSEC7th | $2.3 BSEC2nd | $1.9 BSEC4th | $445 MSEC8th | $7.9 BSEC1st | $1.2 BSEC5th |
| 2017 | $1.5 BSEC4th | $636 MSEC6th | $464 MSEC7th | $2.2 BSEC2nd | $1.8 BSEC3rd | $334 MSEC8th | $7.8 BSEC1st | $1.1 BSEC5th |
| 2016 | $1.1 BSEC4th | $564 MSEC6th | $367 MSEC7th | $2.1 BSEC2nd | $1.6 BSEC3rd | $263 MSEC8th | $7.7 BSEC1st | $1.1 BSEC5th |
| 2015 | $845 MSEC4th | $545 MSEC6th | $264 MSEC7th | $2.0 BSEC2nd | $1.6 BSEC3rd | $186 MSEC8th | $6.0 BSEC1st | $800 MSEC5th |
| 2014 | $762 MSEC4th | $474 MSEC6th | $231 MSEC7th | $2.2 BSEC2nd | $1.8 BSEC3rd | $126 MSEC8th | $4.7 BSEC1st | $688 MSEC5th |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Align Technology, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Globus Medical, Inc.GMED · 🇺🇸 USASame industry: Medical Devices · Similar size: $10.9 B market cap against $10.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $10.9 B (Oct 26, 2026) · revenue $2.9 B (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Insulet CorporationPODD · 🇺🇸 USASame industry: Medical Devices · Similar size: $10.4 B market cap against $10.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $10.4 B (Oct 27, 2026) · revenue $2.7 B (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Bio-Rad Laboratories, Inc.BIO · 🇺🇸 USASame industry: Medical Devices · Similar size: $9.5 B market cap against $10.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $9.5 B (Aug 1, 2026) · revenue $2.6 B (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Bruker CorporationBRKR · 🇺🇸 USASame industry: Medical Devices · Similar size: $9.1 B market cap against $10.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $9.1 B (Oct 27, 2026) · revenue $3.4 B (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Penumbra, Inc.PEN · 🇺🇸 USASame industry: Medical Devices · Similar size: $12.8 B market cap against $10.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $12.8 B (Oct 27, 2026) · revenue $1.4 B (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Zimmer Biomet Holdings, Inc.ZBH · 🇺🇸 USASame industry: Medical Devices · Similar size: $18.2 B market cap against $10.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $18.2 B (Oct 29, 2026) · revenue $8.2 B (year to December 2025)96 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Integer Holdings CorporationITGR · 🇺🇸 USASame industry: Medical Devices · Similar size: $4.3 B market cap against $10.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $4.3 B (Oct 27, 2026) · revenue $1.9 B (year to December 2025)94 of 100 (industry or sector 50 + size 24 + country 15 + figures on file 5)In the group
- AxoGen, Inc.AXGN · 🇺🇸 USASame industry: Medical Devices · Similar size: $3.0 B market cap against $10.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $3.0 B (Oct 30, 2026) · revenue $225 M (year to December 2025)92 of 100 (industry or sector 50 + size 22 + country 15 + figures on file 5)+ Add
- TransMedics Group, Inc.TMDX · 🇺🇸 USASame industry: Medical Devices · Similar size: $2.5 B market cap against $10.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $2.5 B (Oct 27, 2026) · revenue $605 M (year to December 2025)90 of 100 (industry or sector 50 + size 20 + country 15 + figures on file 5)+ Add
- Edwards Lifesciences CorporationEW · 🇺🇸 USASame industry: Medical Devices · Similar size: $52.8 B market cap against $10.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $52.8 B (Oct 29, 2026) · revenue $6.1 B (year to December 2025)90 of 100 (industry or sector 50 + size 20 + country 15 + figures on file 5)+ Add
- Butterfly Network, Inc.BFLY · 🇺🇸 USASame industry: Medical Devices · 5.1× smaller by market cap · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $2.1 B (Oct 29, 2026) · revenue $98 M (year to December 2025)89 of 100 (industry or sector 50 + size 19 + country 15 + figures on file 5)+ Add
- Inspire Medical Systems, Inc.INSP · 🇺🇸 USASame industry: Medical Devices · 5.2× smaller by market cap · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $2.1 B (Oct 21, 2026) · revenue $912 M (year to December 2025)89 of 100 (industry or sector 50 + size 19 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.